BioNTech is trading 4.73% down at $91.84 after broad market weakness; no new company-specific announcement or earnings release clearly explains the after-hours decline.
- BioNTech closed at $96.40 on September 10, 2026.
- The S&P 500 was down 0.55% as investors weighed above-forecast producer inflation, interest-rate uncertainty, and geopolitical pressure.
- Concerns over BioNTech’s discontinued personalized cancer-vaccine trial may also be weighing on sentiment.